Lipid levels correlate with neuronal and dopaminergic markers during the differentiation of SH-SY5Y cells
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 12,6 MB, PDF-dokument
Parkinson's Disease (PD) is characterised by the loss of dopaminergic neurons and the deposition of protein inclusions called Lewy Bodies (LBs). LBs are heterogeneous structures composed of protein and lipid molecules and their main constituent is the presynaptic protein α-synuclein. SH-SY5Y cells are neuroblastoma cells commonly used to model PD because they express dopaminergic markers and α-synuclein and they can be differentiated into neuronal cells using established protocols. Despite increasing evidence pointing towards a role of lipids in PD, limited knowledge is available on the lipidome of undifferentiated and differentiated SH-SY5Y cells. Using a combination of lipidomics, proteomics, morphological and electrophysiological measurements, we identified specific lipids, including sphingolipids, whose levels are affected by the differentiation of SH-SY5Y neuroblastoma cells and found that the levels of these lipids correlate with those of neuronal and dopaminergic markers. These results provide a quantitative characterisation of the changes in lipidome associated with the differentiation of SH-SY5Y cells into more neuronal and dopaminergic-like phenotype and serve as a basis for further characterisation of lipid disruptions in association with PD and its risk factors in this dopaminergic-like neuronal cell model.
Originalsprog | Engelsk |
---|---|
Artikelnummer | 167212 |
Tidsskrift | Biochimica et Biophysica Acta - Molecular Basis of Disease |
Vol/bind | 1870 |
Udgave nummer | 6 |
Antal sider | 8 |
ISSN | 0925-4439 |
DOI | |
Status | Udgivet - 2024 |
Bibliografisk note
Funding Information:
This work was supported by the Independent Research Fund Denmark (2067-00053B (EMS)), Sino-Danish Center for Education and Research (118930 (JNE, KAK)), Lundbeck Foundation (R314-2018-3493 (FRM, CG)), Carlsberg Foundation (CF19-0382 (SSM, FRM, CG)), Novo Nordisk Foundation (NNF20OC0059417 (CG), NNF17OC0029432 (KM)) and Parkinsonforeningen (R16-A250-B174, R37-A805-B174, R54-A1270-B174 (FRM, CG)). We thank the Lipidomics Core Facility (DCI) for access to materials, instrumentations, and expertise.
Publisher Copyright:
© 2024 The Authors
ID: 393775634